Fintel reports that on August 21, 2023, B of A Securities maintained coverage of Rani Therapeutics Holdings Inc (NASDAQ:RANI) with a Buy recommendation.
Analyst Price Forecast Suggests 495.00% Upside
As of August 2, 2023, the average one-year price target for Rani Therapeutics Holdings Inc is 23.20. The forecasts range from a low of 15.15 to a high of $33.60. The average price target represents an increase of 495.00% from its latest reported closing price of 3.90.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Rani Therapeutics Holdings Inc is 0MM, a decrease of NaN%. The projected annual non-GAAP EPS is -1.56.
What is the Fund Sentiment?
There are 48 funds or institutions reporting positions in Rani Therapeutics Holdings Inc. This is a decrease of 4 owner(s) or 7.69% in the last quarter. Average portfolio weight of all funds dedicated to RANI is 0.04%, a decrease of 19.07%. Total shares owned by institutions increased in the last three months by 6.36% to 3,310K shares. 
The put/call ratio of RANI is 1.42, indicating a bearish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 522K shares representing 2.05% ownership of the company. No change in the last quarter.
Nan Fung Group Holdings holds 494K shares representing 1.93% ownership of the company. No change in the last quarter.
United Services Automobile Association holds 481K shares representing 1.89% ownership of the company. No change in the last quarter.
Alphabet holds 448K shares representing 1.76% ownership of the company. No change in the last quarter.
Bank Of America holds 172K shares representing 0.67% ownership of the company. In it's prior filing, the firm reported owning 13K shares, representing an increase of 92.19%. The firm increased its portfolio allocation in RANI by 178.76% over the last quarter.
Rani Therapeutics Holdings Background Information
(This description is provided by the company.)
Rani Therapeutics is a clinical-stage biotech company that has developed a platform technology to enable oral delivery of biologic drugs.
Additional reading:
- Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update - Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Busin
- License and Supply Agreement by and between Rani Therapeutics, LLC and Celltrion, Inc. dated May 26, 2023.
- Employment Agreement, dated May 17, 2023, by and between Rani Therapeutics, LLC and Kate McKinley.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
